Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Christopher N. Graham, Alexandra Christodoulopoulou, Hediyyih N. Knox, Lorenzo Sabatelli, Guy Hechmati, Tamer Garawin & John H. Strickler. (2018) A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. Journal of Medical Economics 21:11, pages 1075-1083.
Read now
Read now
Darya B. Rose, Dave Nellesen, Maureen P. Neary & Beilei Cai. (2017) Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic. Journal of Medical Economics 20:4, pages 395-404.
Read now
Read now
Dominick Latremouille-Viau, Jane Chang, Annie Guerin, Sherry Shi, Ed Wang, Justin Yu & Christopher Ngai. (2017) The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States. Journal of Medical Economics 20:1, pages 54-62.
Read now
Read now
Kelly Lien, Scott Berry, Yoo-Joung Ko & Kelvin KW Chan. (2015) The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?. Expert Review of Pharmacoeconomics & Outcomes Research 15:1, pages 81-100.
Read now
Read now
Benjamin Chastek, Mahesh Kulakodlu, Satish Valluri & Brian Seal. (2013) Impact of Metastatic Colorectal Cancer Stage and Number of Treatment Courses on Patient Health Care Costs and Utilization. Postgraduate Medicine 125:2, pages 73-82.
Read now
Read now
Jessie M Wu & Carolyn A Staton. (2012) Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opinion on Drug Discovery 7:8, pages 723-743.
Read now
Read now
Articles from other publishers (8)
Rui Pei, Yin Shi, Shuhe Lv, Tingting Dai, Fengyu Zhang, Shao Liu & Bin Wu. (2021) Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. JAMA Network Open 4:5, pages e218065.
Crossref
Crossref
Syril D. Pettit & Rebecca Kirch. (2018) Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?. Cardio-Oncology 4:1.
Crossref
Crossref
Yifan Xu, Joel W. Hay & Afsaneh Barzi. (2018) Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Veena Shankaran, Jesse D. Ortendahl, Anna G. Purdum, Bjorn Bolinder, Ayanna M. Anene, Gordon H. Sun & Tanya G.K. Bentley. (2018) Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. American Journal of Clinical Oncology 41:1, pages 65-72.
Crossref
Crossref
Christopher N. Graham, Gregory A. Maglinte, Lee S. Schwartzberg, Timothy J. Price, Hediyyih N. Knox, Guy Hechmati, Jonas Hjelmgren, Beth Barber & Marwan G. Fakih. (2016) Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical Therapeutics 38:6, pages 1376-1391.
Crossref
Crossref
Darshan A. Mehta & Joel W. Hay. (2014) Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. Gynecologic Oncology 132:3, pages 677-683.
Crossref
Crossref
Kamran Bagheri Lankarani. (2013) Why Colorectal Diseases are Important?. Annals of Colorectal Research 1:1, pages 1-2.
Crossref
Crossref
Kamran Bagheri Lankarani. (2013) Why Colorectal Diseases are Important?. Annals of Colorectal Research 1:1.
Crossref
Crossref